The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Lunch Activity/Non-CE-Accredited Satellite Symposium: The Role of APPs in Maximizing Patient Outcomes with DARZALEX® and DARZALEX® FASPRO® +Rd in Patients with Newly Diagnosed, Transplant-Ineligible Multiple Myeloma. <br> Janssen Oncology part of the Pharmaceutical Companies of Johnson & Johnson </br><br><i>Seating available on first-come, first-served basis</br></i>